agenusbio.com

Website review agenusbio.com

Agenus: Better immunotherapies

 Generated on March 28 2026 02:34 AM

Old data? UPDATE !

The score is 54/100

SEO Content

Title

Agenus: Better immunotherapies

Length : 30

Perfect, your title contains between 10 and 70 characters.

Description

Activating the Power of the Immune System to Defeat Cancer

Length : 58

Ideally, your meta description should contain between 70 and 160 characters (spaces included). Use this free tool to calculate text length.

Keywords

Very bad. We haven't found meta keywords on your page. Use this free online meta tags generator to create keywords.

Og Meta Properties

Good, your page take advantage of Og Properties.

Property Content
type website

Headings

H1 H2 H3 H4 H5 H6
2 24 65 0 0 0
  • [H1] Using Your Immune System to Defeat Cancer
  • [H1] Using Your Immune System to Defeat Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Innovative Immunotherapies
  • [H2] Learn how our science is changing what’s possible
  • [H2] Stage III MSS Colorectal Cancer
  • [H2] Merkel Cell Carcinoma
  • [H2] Undifferentiated Pleomorphic Sarcoma
  • [H2] Bringing the Power of Immunotherapy
to More Patients
  • [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
  • [H2] In the News
  • [H2] Get answers about clinical trials, patient access, and more
  • [H2] By the Numbers
  • [H3] OncoDaily
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer

Images

We found 164 images on this web page.

164 alt attributes are empty or missing. Add alternative text so that search engines can better understand the content of your images.

Text/HTML Ratio

Ratio : 5%

This page's ratio of text to HTML code is below 15 percent, this means that your website probably needs more text content.

Flash

Perfect, no Flash content has been detected on this page.

Iframe

Too Bad, you have Iframes on the web pages, this mean that content in an Iframe cannot be indexed.

URL Rewrite

Good. Your links looks friendly!

Underscores in the URLs

Perfect! No underscores detected in your URLs.

In-page links

We found a total of 41 links including 0 link(s) to files

Anchor Type Juice
- Internal Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
- External Passing Juice
Opt-out preferences Internal Passing Juice
Terms and Conditions of Use Internal Passing Juice
Privacy Policy Internal Passing Juice
Community Guidelines Internal Passing Juice
Access to Investigational Medicines Policy Internal Passing Juice
Report Adverse Event Internal Passing Juice
Investor Portal Internal Passing Juice

SEO Keywords

Keywords Cloud

balstilimab patient immunotherapy botensilimab colorectal cancer agenus january news access

Keywords Consistency

Keyword Content Title Keywords Description Headings
cancer 48
access 29
botensilimab 28
agenus 25
colorectal 23

Usability

Url

Domain : agenusbio.com

Length : 13

Favicon

Great, your website has a favicon.

Printability

We could not find a Print-Friendly CSS.

Language

Good. Your declared language is en.

Dublin Core

This page does not take advantage of Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Your declared charset is UTF-8.

W3C Validity

Errors : 0

Warnings : 0

Email Privacy

Warning! At least one email address has been found in the plain text. Use free antispam protector to hide email from spammers.

Deprecated HTML

Great! We haven't found deprecated HTML tags in your HTML.

Speed Tips

Excellent, your website doesn't use nested tables.
Too bad, your website is using inline styles.
Great, your website has few CSS files.
Too bad, your website has too many JS files (more than 6).
Perfect, your website takes advantage of gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimization

XML Sitemap

Great, your website has an XML sitemap.

https://www.agenusbio.com/sitemap.xml

Robots.txt

https://agenusbio.com/robots.txt

Great, your website has a robots.txt file.

Analytics

Missing

We didn't detect an analytics tool installed on this website.

Web analytics let you measure visitor activity on your website. You should have at least one analytics tool installed, but It can also be good to install a second in order to cross-check the data.

PageSpeed Insights

Device
Categories

Free SEO Testing Tool

Free SEO Testing Tool is a free SEO tool which provides you content analysis of the website.